Home › Cytokine Release Syndrome
Cytokine Release Syndrome clinical trials recruiting in the U.S.
9 studies for Cytokine Release Syndrome are recruiting participants at sites across the United States.
By state
Recently updated studies
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07609940Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06806033Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 10, 2026 · NCT06339177Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT05905328Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT07657312Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jun 25, 2026 · NCT06447376Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05972135Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Mar 3, 2026 · NCT05306080Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Recruiting
Ages 21 and older · All sexes · Updated Feb 5, 2026 · NCT07390071From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.